Summary for the U.S. Medicare Population for Indications from Recent Multi-center Studies

The use of PET in just the 4 indications described in the ICP cost-effectiveness studies for the U.S. Medicare population would result in a total gross savings (excluding the cost of providing PET) of:

• Total U.S. Medicare Savings: $1.6 billion per year

The number of invasive procedures and other diagnostic procedures which would be eliminated are:

• Procedures Eliminated: 189,162 per year

The number of PET studies per year required for the four indications described would be:

• Total PET Studies per Year: 388,951 studies

At a projected average cost of $1000 per PET study, the total net savings to Medicare for the 4 indications detailed would be:

• Total Projected Net Cost Savings: $1.2 billion per year

At the current average proposed PET Medicare reimbursement rate of $1790 per PET study, the total net savings to Medicare would be:

• Total Current Net Cost Savings: $0.9 billion per year

Note that this information is only for the indications described in the initial cost-effectiveness PET studies. Additional significant savings are likely as additional cost-effective indications are developed. In addition, these cost savings do not include the additional cost savings due to complications inherent in invasive procedures. Further, no quantifiable benefit is included for the increased mortality and morbidity associated with invasive procedures.